Neurocrine Biosciences
NBIX
#1678
Rank
A$18.61 B
Marketcap
A$185.43
Share price
2.01%
Change (1 day)
-1.33%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$6.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.10. In 2024 the company made an earnings per share (EPS) of A$4.79 an increase over its 2023 EPS that were of A$3.60.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$6.6338.6%
2024A$4.7933.07%
2023A$3.6057.76%
2022A$2.2869.47%
2021A$1.35-78.21%
2020A$6.17990%
2019A$0.5781.82%
2018A$0.31-113.5%
2017A-$2.310.62%
2016A-$2.2957.28%
2015A-$1.4625.61%
2014A-$1.1618.84%
2013A-$0.98-1085.71%
2012A$0.09911

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.93-68.45%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$3.39-44.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$32.59 434.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.04248-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.87-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.42-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$42.34-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.50-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK